等待开盘 11-17 09:30:00 美东时间
-0.105
-9.83%
The latest update is out from SynAct Pharma AB ( ($SE:SYNACT) ). SynAct Pharma ...
11-16 23:32
MetaVia ( ($MTVA) ) has issued an announcement. MetaVia is a clinical-stage bio...
11-16 22:27
Acrivon Therapeutics reported third-quarter 2026 financial results and highlighted progress in its oncology and immunology pipelines. The company expanded its focus into immunology and inflammation, leveraging its AI-driven AP3 platform to identify novel therapies. Key developments include ACR-525, a JAK1 inhibitor targeting eosinophilic esophagitis, and ACR-2316, a WEE1/PKMYT1 inhibitor showing promising safety and efficacy in lung cancers. ACR-...
11-16 21:05
Exicure, Inc. announced it filed a Notification of Late Filing on Form 12b-25 with the SEC due to additional time needed to review its accounting for certain assets and liabilities. The company expects to file its Q3 2026 Form 10-Q within the five-day extension period under Rule 12b-25. Exicure, a biotechnology company focused on nucleic acid therapies, is exploring strategic alternatives to maximize stockholder value following its restructuring.
11-16 21:00
Daré Bioscience received an additional $851,796 under a $10.7 million grant to develop a novel non-hormonal intravaginal contraceptive for women in low- and middle-income countries. This payment is the second-to-last tranche of the grant, supporting ongoing research and development efforts. The company aims to address unmet needs in reproductive health by providing greater choice and autonomy for women.
11-16 14:09
MeiraGTx will present its AAV-BDNF program at ObesityWeek 2026, targeting severe early-onset obesity caused by BDNF haploinsufficiency. The study demonstrates that a single hypothalamic injection of AAV-BDNF restored metabolic and neurobehavioral function in mouse models, with long-term efficacy and safety. This intervention addresses both obesity and neurobehavioral symptoms, offering potential for transformative treatment in rare genetic disord...
11-16 12:00
Zymeworks has launched a second 2026 share repurchase program, authorizing up to $200 million in repurchases through 2028, with $140 million expected to be spent by then. The program offers flexibility to adjust repurchase pace based on market conditions and cash flow. The company aims to balance capital allocation across R&D, M&A, and share repurchases to enhance shareholder value. The program is funded by existing cash and near-term inflows, in...
11-16 11:00
An announcement from Nextbiomedical Co. Ltd. ( ($KR:389650) ) is now available....
11-16 10:24
Pharmaust Limited ( ($AU:NUZ) ) has shared an update. Neurizon Therapeutics is ...
11-16 06:15
Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, highlighted its transformation into a commercial-stage biotech company at the ASX Investor Day. The presentation emphasized the continued growth of Ryoncil® (remestemcel-L-rknd) and the potential to leverage its cellular therapy platform across multiple high-value indications. Key priorities include expanding RYONCIL into adult acute graft-versus-host d...
11-15 23:16